公司简介
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an inj...
关联新闻
- Worried investors are paying up for these stocks — some with up to 49% upside, analysts say
Defensive sectors have beaten the S&P 500 by a wide margin in recent months, even though they are priced much higher relative to earnings estimates than the index.
- Gilead's HIV Franchise Powers Earnings Beat. The Rest Is a Work in Progress.
Gilead Sciences posts higher-than-expected sales as blockbuster HIV drug Biktarvy continues to drive its top line.
- BioNTech, Gilead to test drug combination in advanced breast cancer trial
BioNTech, Gilead to test drug combination in advanced breast cancer trial
- Gilead's pill succeeds in mid-stage bowel disease trial
Gilead's pill succeeds in mid-stage bowel disease trial
- Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets
Shares of AbbVie, Eli Lilly and Gilead Sciences are trading at or near record highs.
- More Upside Awaits for Gilead Sciences Stock. Stay Invested.
Gilead shares are up 35% since Barron's highlighted them, but our catalysts have yet to fully play out.
- Genetic discovery yields clues toward reversal of Alzheimer's brain damage
Today we highlight a discovery with potentially important implications for future Alzheimer's research and treatments. We also report on an experimental Gilead therapy showing great promise against a...
- US FDA approves Gilead's once-daily combination pill for HIV treatment
The U.S. Food and Drug Administration has approved Gilead Sciences' once daily oral combination pill for treatment of adults whose HIV has already been reduced to very low levels, the co...